Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987536 | 0.87 | HSD17B10 (0.51) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL13930850 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL14642164 | 0.84 | CASR (0.41) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL12598436 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL19618135 | 0.83 | SCN4A (0.62) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL14437605 | 0.83 | CASR (0.40) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL13896679 | 0.80 | NPC1 (0.38) | SMN1; SMN2RAB9ANPC1EPHX2SCN4A | |
| SCHEMBL11956363 | 0.78 | EPHX2 (0.65) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 | |
| SCHEMBL19840307 | 0.77 | CSNK1D (0.44) | SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL19965725 | 0.75 | HSD17B10 (0.49) | SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | SMN1; SMN2 4521/4885RAB9A 3832/4885NPC1 2350/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | SMN1; SMN2 4521/4885RAB9A 3832/4885NPC1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.